Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial).
about
Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial).
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Additional hepatic 166Ho-radio ...... e II study (HEPAR PLUS trial).
@en
Additional hepatic 166Ho-radio ...... e II study (HEPAR PLUS trial).
@nl
type
label
Additional hepatic 166Ho-radio ...... e II study (HEPAR PLUS trial).
@en
Additional hepatic 166Ho-radio ...... e II study (HEPAR PLUS trial).
@nl
prefLabel
Additional hepatic 166Ho-radio ...... e II study (HEPAR PLUS trial).
@en
Additional hepatic 166Ho-radio ...... e II study (HEPAR PLUS trial).
@nl
P2093
P2860
P1433
P1476
Additional hepatic 166Ho-radio ...... e II study (HEPAR PLUS trial).
@en
P2093
Arthur J A T Braat
Boen L R Kam
Dik J Kwekkeboom
Gerard C Krijger
Hugo W A M de Jong
Jaap J M Teunissen
Koen M A Dreijerink
Marnix G E H Lam
Maurice A A J van den Bosch
Rob van Rooij
P2860
P2888
P356
10.1186/S12876-018-0817-8
P577
2018-06-15T00:00:00Z
P6179
1104597196